marijuana stocks news

Form 8-K for CV SCIENCES, INC.


11-Feb-2016

Regulation FD Disclosure

Item 7.01 Regulation FD DisclosureOn February 9, 2016, CV Sciences, Inc. formerly CannaVEST Corp. (the “Company”) issued a press release (the “Press Release”) regarding the rejection of the Company’s prepayment by one investor who acquired certain convertible promissory notes issued by the Company by assignment from the lead investor. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Organigram Holdings Inc. (OGRMF) Chosen to Include Award-Winning Sativa Flower, Wabanaki, in World’s First Adult Recreational Cannabis Collections™ Variety Kit

Organigram Chosen to Include Award-Winning Sativa Flower, Wabanaki, in World’s First Adult…

CLS Holdings USA, Inc. (CLSH) Oasis Cannabis Dispensary Hosts 2,000 Guests Over Grand Reopening Weekend

Oasis Cannabis Dispensary Hosts 2,000 Guests Over Grand Reopening Weekend Oasis Cannabis,…

Greenlane Holdings, Inc. (GNLN) to Host Fourth Quarter 2022 Conference Call on April 3, 2023

Greenlane to Host Fourth Quarter 2022 Conference Call on April 3, 2023…

Tetra Bio-Pharma Inc. (TBPMF) FDA Provides Positive Feedback on Pre-Investigational New Drug Application for ARDS-003

FDA Provides Positive Feedback on Tetra Bio-Pharma’s Pre-Investigational New Drug Application for…